Call for EOIs: Innovation in Life Sciences (UK)

These projects apply emerging digital technologies, such as supercomputing, data analytics, artificial intelligence (AI), machine learning and quantum computing, to industrially relevant and impactful research and innovation to further drug discovery and precision medicine in the UK.

The consortium are seeking project proposals that will leverage newly developed and existing digital technologies to improve the speed, accuracy, and efficiency of solutions within the life sciences sector.

Themes

• The Innovation in Life Sciences call will focus on the following themes of:
  • Drug discovery
  • Personalised medicine and treatment recommendations
  • Patient-specific responses to drug treatment
  • Predictive analytics for patient outcomes

Focus Areas

• The applicable technology areas for consideration are but not limited to:
  • AI enhanced modelling and simulation
  • AI enhanced data analytics
  • Scalable AI
  • Exascale computing
  • Quantum computing

Funding Information

• The Innovation in Life Sciences competition is offering up to 72 months of staff time (combined from STFC and IBM resources) and compute resources to enable the initiation of between 4-8 projects to commence between April 2025 to June 2025 (and conclude by March 2026). This corresponds to an allocation of approximately £2-3 M of the total HNCDI budget (£210m) that will fund STFC and IBM staff time and cloud/computing access. No direct funding is available to organisations outside of the HNCDI partners.
• Most projects are anticipated to fall in the 3 – 12 month timeframe, with maximum project duration being fixed at 12 months.

Eligibility Criteria

• To be eligible for participation to the submission and project delivery phases, your organisation must:
  • be a UK based business of any size registered at Companies House;
  • have a development base for the relevant product or service in the UK or provide the relevant product or service from or in the UK;
  • if “in kind contribution” is provided, carry out its project work in the UK;
  • intend to exploit the results from or in the UK;
  • start the project in the window between 1 April 2025 to 1 June 2025;
  • end the project by 31 March 2026.

For more information, visit Bionow.